Boston Scientific Corp(BSX-N)
NYSE

Today's Change
Real-Time Last Update Last Sale Cboe BZX Real-Time
Day Low51.70
Day High52.99
Open:52.83
Price movement based on the high, low and last over the given period.
Previous Close
52-Week High/Low
Volume
Average Volume
Price/Earnings (TTM)
Forward Annual Dividend & Yield
Market Capitalization, $M
5-Day Change
Realtime quote and/or trade prices are not sourced from all markets.
Select a category then submit the form to load news
Tipranks
Citi Keeps Their Buy Rating on Boston Scientific (BSX)
Tipranks
Boston Scientific’s MANDARIN Trial Shines Spotlight on Liver Cancer Strategy in China
Zacks Investment Research
Edwards Climbs 14% in 3 Months as Growth Strength Tests Valuation
Edwards Climbs 14% in 3 Months as Growth Strength Tests Valuation
Zacks Investment Research
What's Backing Abbott's Established Pharmaceuticals Division Growth
What's Backing Abbott's Established Pharmaceuticals Division Growth
Tipranks
Bank of America Securities Reaffirms Their Buy Rating on Boston Scientific (BSX)
Motley Fool
Boston Scientific Director Habiger Buys $100k of Shares Amid 54% Decline. What Does This Mean for BSX in 2026?
Motley Fool
Boston Scientific CEO Mahoney Buys More Than 200k Shares for $10 Million. What Does This Mean for Investors in 2026?
Zacks Investment Research
Should You Buy, Hold or Sell ABT Stock Amid Medical Devices Boom?
Should You Buy, Hold or Sell ABT Stock Amid Medical Devices Boom?
Motley Fool
Boston Scientific (BSX) Q2 2026 Earnings Call Transcript
Zacks Investment Research
Boston Scientific's 2026 Guidance Cut Puts Its Recovery to the Test
Boston Scientific's 2026 Guidance Cut Puts Its Recovery to the Test
Tipranks
Boston Scientific’s Long-Term ESG Study: What Termination Means for Obesity Investment Sentiment
StockStory
Boston Scientific’s Q2 Earnings Call: Our Top 5 Analyst Questions
BSX
Tipranks
Analysts Have Conflicting Sentiments on These Healthcare Companies: Humana (HUM), Boston Scientific (BSX) and Acadia Healthcare (ACHC)
Tipranks
Analysts Are Neutral on Top Healthcare Stocks: Boston Scientific (BSX), Capricor Therapeutics (CAPR)
Tipranks
Boston Scientific Balances Earnings Beat With Cautious Outlook
Tipranks
Analysts’ Opinions Are Mixed on These Healthcare Stocks: Teladoc (TDOC) and Boston Scientific (BSX)
Tipranks
Analysts Offer Insights on Healthcare Companies: Rezolute (RZLT) and Boston Scientific (BSX)
Zacks Investment Research
BSX Q2 Earnings Call Highlights WATCHMAN and EP Pressure
BSX Q2 Earnings Call Highlights WATCHMAN and EP Pressure
Tipranks
Jefferies Reaffirms Their Buy Rating on Boston Scientific (BSX)

Profile

Boston Scientific Corporation manufactures medical devices and products used in various interventional medical specialties worldwide. The company has adopted the organic as well as inorganic routes for success. Boston Scientific currently has 3 global reportable segments - Cardiovascular, Rhythm and Neuro and MedSurg. While Cardiovascular includes Interventional Cardiology and Peripheral Interventions, Rhythm and Neuro comprises Cardiac Rhythm Management, Electrophysiology and Neuromodulation. The MedSurg group comprises 2 sub segments, viz. Endoscopy, Urology and Pelvic Health. Boston Scientific markets a broad portfolio of internally-developed and self-manufactured drug eluting stents including the Promus PREMIER, Promus Element and Promus Element Plus everolimus-eluting stents. Within the CRM segment, the company deals with implantable devices that monitor the heart and deliver electricity to treat cardiac abnormalities.

All market data (will open in new tab) is provided by Barchart Solutions. Copyright © 2026.

Information is provided 'as is' and solely for informational purposes, not for trading purposes or advice. For exchange delays and terms of use, please read disclaimer (will open in new tab).

Copyright © 2026 Morningstar. All Rights Reserved. The information contained herein: (1) is proprietary to Morningstar and/or its content providers; (2) may not be copied or distributed; and (3) is not warranted to be accurate, complete or timely. Neither Morningstar nor its content providers are responsible for any damages or losses arising from any use of this information. Past performance is no guarantee of future results.